FiercePharmaOriginal article
{"a":[{"_":"FDA deepens Vertex's Casgevy label, opening treatment for patients as young as 2","$":{"href":"/pharma/fda-expands-use-vertexs-casgevy-patients-age-2-and-older","hreflang":"en"}}]}
RegulatoryapprovedCasgevyPositive
AI Analysis
Summary
The FDA has expanded Casgevy's label to include children as young as 2 years old for treating sickle cell disease and transfusion-dependent beta thalassemia, broadening the gene therapy's addressable patient population beyond the previously approved ages 12 and older.
Outcome Details
Label expansion approved for patients ages 2 and older; previously approved for patients ages 12 and older
Importance:7/10
Sentiment:
0.80
FDA approvallabel expansiongene therapypediatric indicationsickle cell diseasebeta thalassemia
Related Companies
Read the original article
Published by FiercePharma on July 6, 2026 10:36 AM